Hudson Bay Capital Management
OBIO icon

Hudson Bay Capital Management’s Orchestra BioMed OBIO Stock Holding History

Hudson Bay Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-71,134
Closed -$302K – 1584
2026
Q1 		$302K Buy
71,134
+21,709
+44% +$92.4K ﹤0.01% 1031
2025
Q4 		$205K Buy
+49,425
New +$199K ﹤0.01% 967
2022
Q3 		– Sell
-275,298
Closed -$2.74M – 1313
2022
Q2 		$2.74M Buy
+275,298
New +$2.74M 0.02% 688

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Hudson Bay Capital Management's OBIO Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Orchestra BioMed (OBIO) in Q2 2026, closing a stake of 71,134 shares — an estimated $302K sold.

Hudson Bay Capital Management first reported a position in OBIO in Q2 2022 and held it in 3 quarters. The position peaked at $2.74M in Q2 2022. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Orchestra BioMed position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 71,134 Orchestra BioMed shares in Q2 2026, an estimated $302K.
  • Hudson Bay Capital Management first reported a position in Orchestra BioMed in Q2 2022 and held it in 3 quarters.
  • Hudson Bay Capital Management's Orchestra BioMed position peaked at $2.74M in Q2 2022.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.